Early Detection Research Network

Prostate

Blood protein markers that provide more accurate or earlier diagnosis of prostate cancer should have a positive impact on prostate cancer treatment and management. Experimental evidence shows that thrombospondin-1 levels are elevated in patients with benign prostatic disease and repressed in patients with prostate cancer. Thrombospondin-1 levels do not correlate with prostate-specific antigen (PSA) levels and differentiate benign from malignant disease with 79% sensitivity and 81% specificity. The measurement of thrombospondin-1 could be used to assist the decision to obtain a biopsy in men with suspected prostate cancer, which could lead to a reduction in the number of unnecessary prostatic biopsies.
http://edrn.jpl.nasa.gov/bmdb/biomarkers/organs/54/75
Accepted
Two
d05c5e5e407e40719a23d8492f154160
TSP did not, for the populations tested in these experiments, show strong pre-diagnostic performance. This biomarker has not moved on to Phase 3 study.
8591e8b29d1543d691241e7a3f33de65
no
no
Contents